Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus
Open Access
- 12 January 2023
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (5) , 551-559
Abstract
Evidence shows that sodium‐glucose cotransporter 2 inhibitors, such as dapagliflozin, can delay the progressive decline of kidney function in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). We used a population pharmacokinetics (popPK) model to characterize the pharmacokinetics of dapagliflozin in patients with CKD and compare dapagliflozin systemic exposure in different populations, such as CKD with or without T2DM and T2DM without CKD. A 2‐compartmental popPK model was developed from a previous popPK model. The final popPK model was based on 9715 dapagliflozin plasma concentrations from 3055 patients included in clinical studies involving adults with CKD with or without T2DM, adults with T2DM, healthy subjects, and pediatric patients with T2DM. Overall, the apparent clearance for patients treated with dapagliflozin was 21.6 L/h, similar to previous estimates in adults with T2DM and healthy subjects (22.9 L/h). Model‐derived area under the plasma concentration–time curve (AUC) was not meaningfully different between patients with CKD with and without T2DM. Median AUC was 1.6‐fold higher in adult patients with CKD with T2DM compared with adult patients with T2DM without CKD. Compared with patients with normal kidney function (estimated glomerular filtration rate ≥90 mL/min/1.73 m2), median AUC was 2.4‐fold higher in patients with CKD (with/without T2DM) with estimated glomerular filtration rate 15–29 mL/min/1.73 m2 owing to decreased renal clearance of dapagliflozin. A higher AUC was observed in patients with a higher age or lower body weight but was not considered clinically relevant. This popPK model adequately described dapagliflozin pharmacokinetics and found that systemic exposure in patients with CKD was consistent, irrespective of T2DM status.Keywords
Funding Information
- AstraZeneca
This publication has 19 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetesDiabetes, Obesity and Metabolism, 2018
- Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2016
- Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2016
- Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trialDiabetic Medicine, 2014
- Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) stagingBMC Research Notes, 2014
- Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2Regulatory Toxicology and Pharmacology, 2013
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Clinical Pharmacokinetics, 2013
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 yearsDiabetes, Obesity and Metabolism, 2013
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy SubjectsClinical Pharmacology & Therapeutics, 2009